GenetiSure Dx Postnatal Assay Publications and Guidelines
1. Queißer-Luft , A., and Spranger, J. Congenital Malformations. Dtsch Arztebl, 103(38), 2464-2471 (2006).
2. Jones, K.L., and Adam, M.P. Evaluation and Diagnosis of the Dysmorphic Infant. Clin Perinatol, 42(2), 243 (2015)
3. Mandell, D.S., et al. Factors associated with age of diagnosis among children with autism spectrum disorders. Pediatrics, 116(6), 1480-1486 (2005).
4. Elsabbagh, M., et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res, 5(3), 160-179 (2012).
5. Boyle, C.A., et al. Trends in the prevalence of developmental disabilities in US children. Pediatrics, 127(6), 1034-1042 (2011).
6. Hunter, A.G.W. Medical genetics: 2. The diagnostic approach to the child with dysmorphic signs. CMAJ, 167(4), 367-372 (2002).
7. Kaufman, L., et al. The genetic basis of non-syndromic intellectual disability: A review. J Neurodevelop Disord, 2, 182-209 (2010).
8. Satya-Murti, S., et al. Chromosomal Microarray Analysis for Intellectual Disabilities. American Academy of Neurology (2013).
9. Michelson, D.J., et al. Evidence report: Genetic and metabolic testing on children with global developmental delay, Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 77(17), 1629–1635 (2011).
10. South, S.T., et al. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: Revision 2013. Genet Med Genet Med, 15(11), 901-909 (2013).
11. Vermeesch, J.R., et al. Guidelines for molecular karyotyping in constitutional genetic diagnosis. Eur J Hum Genet, 15, 1105-1114 (2007).
12. Miller, D.T., et al. Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet, 86(5), 749-764 (2010).
13. Kiang, J.U., and Koo, S.H. Evolving applications of microarray technology in postnatal diagnosis (Review). Int J Mol Med, 30, 223-228 (2012).
14. Lyle, R., et al. Genotype – Phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum, 17(4), 454-466 (2009).
INTENDED USE: GenetiSure Dx Postnatal Assay is a qualitative assay intended for the postnatal detection of copy-number variations (CNV) and copy-neutral loss of heterozygosity (cnLOH) in genomic DNA obtained from peripheral whole blood in patients referred for chromosomal testing based on clinical presentation. GenetiSure Dx Postnatal Assay is intended for the detection of CNVs and cnLOH associated with developmental delay, intellectual disability, congenital anomalies or dysmorphic features. Assay results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmation by alternative methods, parental evaluation, clinical genetic evaluation and counseling, as appropriate. Interpretation of assay results is intended to be performed only by healthcare professionals who are board-certified in clinical cytogenetics or molecular genetics.
The assay is intended to be used on the SureScan Dx Microarray Scanner System and analyzed by CytoDx Software.
WARNING: This device is not intended to be used for standalone or diagnostic purposes, pre-implantation or prenatal testing or screening, population screening or the detection of, or screening for, acquired or somatic genetic aberrations.
The products referenced on this page are not available for sale in all countries or jurisdictions. The information contained in this website may not be valid in your jurisdictions. Please contact your local sales representative for additional information.